Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Efficacy Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
The efficacy data wasn't strong enough and i felt that even a small number of parents who moved forward winning it with they were hoping for. it's got moderna looking good, and will probably find out in the coming weeks set of three dose pfizer series will work as well. when that happens, it will be a very different situation for a lot of families, like mine, because we do alter our behavior to keep our four year old safe. honestly, it's been a long time coming and the fda needs to move. >> the problem is people like yourself will get your under five -- under 11 boosted, but sadly, our child v...
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
All children. i also mentioned, dr. reiner, the city in china where a million people are now under lockdown after just one positive case in the city. and that follows the brutal lockdowns that we've been watching play out in shanghai and beyond in china. this comes back to china being so committed to its zero covid strategy. what does this say to you about that zero covid strategy and where this goes from here? >> well, it can't work in china. the problem in china is that they have vaccinated an enormous number of people. almost 87% of their population has received at least one shot. an amazin...
Group. this were no cases of myo carditis, however they pointed out a flaw saying they did not include all the diagnostic codes which may have accounted for not being able to catch some of of the rare cases. for me, i can say the decision to boost healthy adolescence, millions potentially without any efficacy data, you know, is perplexing, and i have to imagine that i don't know if that would have happened if you still had some of those higher level directors there in the summer that quit over the booster controversy. you know, i think that boosters should be targeted for high risk populations...